Merck Seeks Oxytrol Switch For Women As First Overactive Bladder OTC
This article was originally published in The Tan Sheet
Executive Summary
Merck will present to FDA’s Nonprescription Drugs Advisory Committee Nov. 9 in support of switching Watson’s Oxytrol as a female-specific OTC.
You may also be interested in...
Anthrax MedKit Initiative Could Learn From OTC Studies – NDAC
FDA’s Nonprescription Drugs Advisory Committee recommends the HHS sponsors of an antibiotic MedKit take lessons from OTC drug development. But many advisory panel members at an April 2 meeting did not see clear benefits of allowing home stockpiling of doxycycline to treat anthrax.
FDA Advisors Say Greater Insight Needed On Self-Selection Of OTC Statins
More information from "real world" experiences on how consumers make OTC selections may be needed to pull off a successful Rx-to-OTC switch of a statin
Overactive Bladder Category Switch Prospects Questioned By Indevus
Self-selection problems will likely complicate potential Rx-to-OTC switches in the overactive bladder (OAB) category, Indevus Pharmaceuticals execs maintained during an Aug. 9 third quarter earnings call